Vaccine produces long-lasting anti-tumor response in patients with melanoma

Modelling study estimates impact of ‘test to release’ strategy for contacts of COVID-19 cases
21 January 2021
Pain-relief regimen treats trauma patients with fewer opioid drugs
21 January 2021

Vaccine produces long-lasting anti-tumor response in patients with melanoma

Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute of MIT and Harvard report in a new study.

Comments are closed.